Sökning: WFRF:(Van de Werf Frans J.) >
Use of thienopyridi...
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar : insights from the TRACER trial
-
- Harskamp, Ralf E. (författare)
- Univ Amsterdam, Acad Med Ctr, Ctr Heart, Amsterdam, Netherlands.
-
- Clare, Robert M. (författare)
- Duke Clin Res Inst, Box 3850,2400 Pratt St, Durham, NC 27705 USA.
-
- Ambrosio, Giuseppe (författare)
- Univ Perugia, Sch Med, Div Cardiol, Perugia, Italy.
-
visa fler...
-
- Held, Claes, 1956- (författare)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
- Lokhnygina, Yuliya (författare)
- Duke Clin Res Inst, Box 3850,2400 Pratt St, Durham, NC 27705 USA.
-
- Moliterno, David J. (författare)
- Univ Kentucky, Gill Heart Inst, Lexington, KY USA.;Univ Kentucky, Div Cardiovasc Med, Lexington, KY USA.
-
- White, Harvey D. (författare)
- Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.;Univ Auckland, Auckland, New Zealand.
-
- Aylward, Philip E. (författare)
- Flinders Univ & Med Ctr, SAHMRI, Adelaide, SA, Australia.
-
- Armstrong, Paul W. (författare)
- Univ Alberta, Div Cardiol, Edmonton, AB, Canada.
-
- Mahaffey, Kenneth W. (författare)
- Stanford Univ, Dept Med, Stanford, CA 94305 USA.
-
- Harrington, Robert A. (författare)
- Stanford Univ, Dept Med, Stanford, CA 94305 USA.
-
- Van de Werf, Frans (författare)
- Univ Hosp, Dept Cardiol, Leuven, Belgium.
-
- Wallentin, Lars, 1943- (författare)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
- Strony, John (författare)
- Johnson & Johnson, New Brunswick, NJ USA.;Merck, Whitehouse Stn, NJ USA.
-
- Tricoci, Pierluigi (författare)
- Duke Clin Res Inst, Box 3850,2400 Pratt St, Durham, NC 27705 USA.
-
visa färre...
-
Univ Amsterdam, Acad Med Ctr, Ctr Heart, Amsterdam, Netherlands Duke Clin Res Inst, Box 3850,2400 Pratt St, Durham, NC 27705 USA. (creator_code:org_t)
- 2016-09-20
- 2017
- Engelska.
-
Ingår i: European Heart Journal. - : SAGE PUBLICATIONS LTD. - 2048-8726 .- 2048-8734. ; 6:2, s. 155-163
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Vorapaxar is effective in the prevention of secondary atherothrombotic events, although the efficacy/safety balance appears less favorable in the treatment of patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS). We hypothesized that patients with NSTE ACS already receiving thienopyridine prior to the ACS event may show differential efficacy/safety effects with vorapaxar vs. placebo added to their standard care. Methods: We studied 12,944 patients from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial with respect to thienopyridine use before admission for the index NSTE ACS event. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, rehospitalization for ischemia, and urgent revascularization. The key secondary endpoint was a composite of cardiovascular death, myocardial infarction, and stroke. Safety endpoints were bleeding complications. Results: Only 1513 patients (11.7%) were receiving thienopyridine before admission for the index NSTE ACS event. In these patients, Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) moderate/severe bleeding occurred in 5.7% treated with vorapaxar and 5.3% treated with a placebo (hazards ratio (HR) 1.10, 95% confidence interval (CI) 0.70-1.71); in thienopyridine-naive patients, the rates were 5.7% and 4.1%, respectively (HR 1.32, 95% CI 1.11-1.57; P-int=0.45). GUSTO severe bleeding in the prior thienopyridine group occurred in 0.5% of patients treated with vorapaxar and 1.3% of patients treated with placebo (HR 0.34, 95% CI 0.09-1.30); in thienopyridine-naive patients, the rates were 2.0% and 1.0%, respectively (HR 1.89, 95% CI 1.36-2.62; P-int=0.01). No interaction was observed between vorapaxar efficacy and prior thienopyridine use on the primary (adjusted P-int=0.53) or key secondary endpoints (P-int=0.61). Conclusions: TRACER was largely conducted in thienopyridine-naive patients with unknown tolerance to multiple antiplatelet treatments. Patients receiving thienopyridine before the index event may have had an attenuated increase in bleeding when adding vorapaxar, whereas concomitantly adding vorapaxar and thienopyridine in naive patients may have uncovered a latent susceptibility to bleeding.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Vorapaxar
- thienopyridine
- acute coronary syndrome
- outcomes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Harskamp, Ralf E ...
-
Clare, Robert M.
-
Ambrosio, Giusep ...
-
Held, Claes, 195 ...
-
Lokhnygina, Yuli ...
-
Moliterno, David ...
-
visa fler...
-
White, Harvey D.
-
Aylward, Philip ...
-
Armstrong, Paul ...
-
Mahaffey, Kennet ...
-
Harrington, Robe ...
-
Van de Werf, Fra ...
-
Wallentin, Lars, ...
-
Strony, John
-
Tricoci, Pierlui ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
European Heart J ...
- Av lärosätet
-
Uppsala universitet